485 related articles for article (PubMed ID: 24747441)
1. An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.
Seguin L; Kato S; Franovic A; Camargo MF; Lesperance J; Elliott KC; Yebra M; Mielgo A; Lowy AM; Husain H; Cascone T; Diao L; Wang J; Wistuba II; Heymach JV; Lippman SM; Desgrosellier JS; Anand S; Weis SM; Cheresh DA
Nat Cell Biol; 2014 May; 16(5):457-68. PubMed ID: 24747441
[TBL] [Abstract][Full Text] [Related]
2. Integrin β3 links therapy resistance and cancer stem cell properties.
Kannan N; Nguyen LV; Eaves CJ
Nat Cell Biol; 2014 May; 16(5):397-9. PubMed ID: 24914436
[TBL] [Abstract][Full Text] [Related]
3. Integrin-mediated resistance to epidermal growth factor receptor-targeted therapy: an inflammatory situation.
Brown WS; Wendt MK
Breast Cancer Res; 2014 Sep; 16(5):448. PubMed ID: 25255930
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Achilles' heel of drug-resistant cancer stem cells.
Seguin L; Gozo M; Weis SM; Cheresh DA
Cell Cycle; 2014; 13(13):2017-8. PubMed ID: 24906000
[No Abstract] [Full Text] [Related]
5. Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancer.
Kim YJ; Baek DS; Lee S; Park D; Kang HN; Cho BC; Kim YS
Cancer Lett; 2019 Dec; 466():23-34. PubMed ID: 31521695
[TBL] [Abstract][Full Text] [Related]
6. Reversal of EGFR inhibitors' resistance by co-delivering EGFR and integrin αvβ3 inhibitors with nanoparticles in non-small cell lung cancer.
He F; Wang Y; Cai W; Li M; Dong L
Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31316001
[No Abstract] [Full Text] [Related]
7. Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin.
Corominas-Faja B; Oliveras-Ferraros C; Cuyàs E; Segura-Carretero A; Joven J; Martin-Castillo B; Barrajón-Catalán E; Micol V; Bosch-Barrera J; Menendez JA
Cell Cycle; 2013 Nov; 12(21):3390-404. PubMed ID: 24047698
[TBL] [Abstract][Full Text] [Related]
8. Osteopontin promotes a cancer stem cell-like phenotype in hepatocellular carcinoma cells via an integrin-NF-κB-HIF-1α pathway.
Cao L; Fan X; Jing W; Liang Y; Chen R; Liu Y; Zhu M; Jia R; Wang H; Zhang X; Zhang Y; Zhou X; Zhao J; Guo Y
Oncotarget; 2015 Mar; 6(9):6627-40. PubMed ID: 25749383
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.
Diep CH; Munoz RM; Choudhary A; Von Hoff DD; Han H
Clin Cancer Res; 2011 May; 17(9):2744-56. PubMed ID: 21385921
[TBL] [Abstract][Full Text] [Related]
10. Contributions of KRAS and RAL in non-small-cell lung cancer growth and progression.
Guin S; Ru Y; Wynes MW; Mishra R; Lu X; Owens C; Barn AE; Vasu VT; Hirsch FR; Kern JA; Theodorescu D
J Thorac Oncol; 2013 Dec; 8(12):1492-501. PubMed ID: 24389431
[TBL] [Abstract][Full Text] [Related]
11. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.
Tang Z; Du R; Jiang S; Wu C; Barkauskas DS; Richey J; Molter J; Lam M; Flask C; Gerson S; Dowlati A; Liu L; Lee Z; Halmos B; Wang Y; Kern JA; Ma PC
Br J Cancer; 2008 Sep; 99(6):911-22. PubMed ID: 19238632
[TBL] [Abstract][Full Text] [Related]
12. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
[TBL] [Abstract][Full Text] [Related]
13. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
14. The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors.
Chang X; Izumchenko E; Solis LM; Kim MS; Chatterjee A; Ling S; Monitto CL; Harari PM; Hidalgo M; Goodman SN; Wistuba II; Bedi A; Sidransky D
PLoS One; 2013; 8(7):e68966. PubMed ID: 23935914
[TBL] [Abstract][Full Text] [Related]
15. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
[TBL] [Abstract][Full Text] [Related]
16. A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer.
Park J; Cho YH; Shin WJ; Lee SK; Lee J; Kim T; Cha PH; Yang JS; Cho J; Min DS; Han G; Lee HY; Choi KY
Sci Rep; 2019 Jan; 9(1):648. PubMed ID: 30679620
[TBL] [Abstract][Full Text] [Related]
17. Targeting the K-Ras--JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation.
Okada M; Shibuya K; Sato A; Seino S; Suzuki S; Seino M; Kitanaka C
Oncotarget; 2014 Jul; 5(13):5100-12. PubMed ID: 24947996
[TBL] [Abstract][Full Text] [Related]
18. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.
Gazdar AF
Oncogene; 2009 Aug; 28 Suppl 1(Suppl 1):S24-31. PubMed ID: 19680293
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
20. Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response.
Sangodkar J; Dhawan NS; Melville H; Singh VJ; Yuan E; Rana H; Izadmehr S; Farrington C; Mazhar S; Katz S; Albano T; Arnovitz P; Okrent R; Ohlmeyer M; Galsky M; Burstein D; Zhang D; Politi K; Difeo A; Narla G
J Clin Invest; 2012 Jul; 122(7):2637-51. PubMed ID: 22653055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
